2-[2-[2-(Methylamino)ethoxy]ethoxy]acetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[2-[2-(Methylamino)ethoxy]ethoxy]acetamide
• 化学式: C₇H₁₆N₂O₃
• 分子量: 176.21
• InChiKey: ZUWVLFPSZFPDAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  73.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
  申请人：Janssen Pharmaceutica NV

  公开号：EP3532486B1

  公开（公告）日：2021-09-22
• PHOTOSENSITIZER-METAL NANOPARTICLE COMPLEX AND COMPOSITION CONTAINING THE COMPLEX FOR PHOTODYNAMIC THERAPY OR DIAGNOSIS
  申请人：Choi Yong-Doo

  公开号：US20110293728A1

  公开（公告）日：2011-12-01

  Provided are a photosensitizer-metal nanoparticle complex and a composition for photodynamic therapy or diagnosis having the same. The complex includes a photosensitizer, a metal nanoparticle, and a backbone linking the photosensitizer with the metal nanoparticle. The backbone has a polypeptide substrate capable of being specifically degraded by a protease. When the complex is administered to a patient, fluorescence and production of reactive oxygen species from the conjugated photosensitizers are inhibited in normal tissues due to the resonance energy transfer between the photosensitizer and metal nanoparticles, but in tumor tissues, fluorescence and production of reactive oxygen species from the released photosensitizers are activated, thereby effectively destroying the tumor tissues. In addition, the selective fluorescence in the tumor tissues can further improve accuracy of tumor diagnosis using the protease-activatable photosensitizer-metal nanoparticle complex.
• US9339557B2
  申请人：——

  公开号：US9339557B2

  公开（公告）日：2016-05-17
• [EN] CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY<br/>[FR] PROTÉINES CONJUGUÉES À EFFICACITÉ IN VIVO PROLONGÉE
  申请人：NOVO NORDISK AS

  公开号：WO2010015668A1

  公开（公告）日：2010-02-11

  The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing said conjugates, to pharmaceutical compositions comprising said conjugates and to the use of the conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.